Projects per year
Introduction: Gene therapy is becoming increasingly common in clinical practice, giving hope for the correction of a wide range of human diseases and defects. The CRISPR/Cas9 system, consisting of the Cas9 nuclease and single-guide RNA (sgRNA), has revolutionized the field of gene editing. However, efficiently delivering the CRISPR-Cas9 to the target organ or cell remains a significant challenge. In recent years, with rapid advances in nanoscience, materials science, and medicine, researchers have developed various technologies that can deliver CRISPR-Cas9 in different forms for in vitro and in vivo gene editing. Here, we review the development of the CRISPR-Cas9 and describe the delivery forms and the vectors that have emerged in CRISPR-Cas9 delivery, summarizing the key barriers and the promising strategies that vectors currently face in delivering the CRISPR-Cas9. Areas covered: With the rapid development of CRISPR-Cas9, delivery methods are becoming increasingly important in the in vivo delivery of CRISPR-Cas9. Expert opinion: CRISPR-Cas9 is becoming increasingly common in clinical trials. However, the complex nuclease and protease environment is a tremendous challenge for in vivo clinical applications. Therefore, the development of delivery methods is highly likely to take the application of CRISPR-Cas9 technology to another level.
|Number of pages||14|
|Journal||Expert Opinion on Drug Delivery|
|Publication status||Published - 17 Jul 2022|
|MoE publication type||A2 Review article in a scientific journal|
FingerprintDive into the research topics of 'Progress of delivery methods for CRISPR-Cas9'. Together they form a unique fingerprint.
- 2 Active
FCFH: Finland-China Network in Food and Health Sciences
Rosenholm, J., Xu, C. & Zhang, H.
Ministry of Education and Culture
01/01/21 → 31/12/24
Project: Ministry / Government Agency
Targeted delivery of CRISPR/Cas9 for advanced liver cancer therapy through c-Myc knockout
01/09/19 → 31/08/24
Project: Academy of Finland/Other Research Councils